Biozone Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.80 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.80 Cr
as on 24-10-2024
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.12 Cr
as on 24-10-2024
- Satisfied Charges ₹ 3.75 Cr
as on 24-10-2024
- Revenue %
(FY 2023)
- Net Worth 0.70%
(FY 2023)
- Total Assets 7.42%
(FY 2023)
About Biozone Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.80 Cr and a paid-up capital of Rs 1.80 Cr.
The company currently has active open charges totaling ₹3.12 Cr. The company has closed loans amounting to ₹3.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Damaninder Jaijee, Ritika Oberoi, Harish Oberoi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24302PN2016PTC164227
- Company No.
164227
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Apr 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Ahmed Nagar, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Biozone Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Damaninder Jaijee  | Director | 08-Jun-2020 | Current |
| Ritika Oberoi | Additional Director | Current | |
| Harish Oberoi | Additional Director | Current | |
| Nimisha Oberoi | Director | 25-May-2022 | Current |
Financial Performance of Biozone Life Sciences.
Biozone Life Sciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 0.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Biozone Life Sciences?
In 2022, Biozone Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Striding Horizon Private LimitedActive 6 years 3 months
Damaninder Jaijee and Ritika Oberoi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Jul 2024 | ₹3.12 Cr | Open |
Bank Of India Creation Date: 09 Apr 2021 | ₹1.25 Cr | Satisfied |
Bank Of India Creation Date: 09 Apr 2021 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Biozone Life Sciences?
Unlock and access historical data on people associated with Biozone Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biozone Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biozone Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
